
Breckenridge propranolol capsules recalled for potential metal contamination
Breckenridge Pharmaceutical is voluntarily recalling one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, manufactured by Adare Pharma Solutions, due to potential metal contamination. The company says use of the affected lot could potentially cause lacerations, or cuts, to soft tissues in the mouth, esophagus, stomach or intestine. Breckenridge is not aware of any related adverse events, and the lot was distributed nationwide between October 26 and November 4, 2026.
From the FDA notice · Read the official notice ↗ · All Breckenridge recalls
What to do
- Talk to your pharmacist or prescriber before stopping this medicine, and ask them for replacement instructions.
- Check whether you have Breckenridge Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, 100-count bottle, NDC 51991-817-01, lot PK25110035, expiration May 2029.
- Return any unused capsules from this lot to the pharmacy where you got them.
- Contact your physician or healthcare provider if you have had any problems that may be related to this product.
- For questions about the recall, call Qualanex at 1-855-736-0807 (Monday to Friday, 9 a.m. to 5 p.m. Eastern) or email recall@qualanex.com.
Is yours affected?
Compare your label or packaging with the recalled product.
- UPC code
- 351991817017
- Sold in
- Nationwide
- Made for
- Adults (0 months and older)
Photos from the FDA
Details
- Illnesses reported
- None reported
In the FDA's words
November 16, 2026 — Breckenridge Pharmaceutical, Inc. (Breckenridge) is voluntarily recalling to the consumer level one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, manufactured by Adare Pharma Solutions, due to potential metal contamination.
Risk Statement
Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine. The affected lot shared intermediate material suspected to be the source of metal contamination identified in a separate lot that was not released to market. To date, Breckenridge is not aware of any adverse events assessed to be related to this recall. Product from the affected lot subject to this recall was distributed nationwide to wholesalers and pharmacies between October 26, 2026 and November 04, 2026.
Read the full announcementShow less
Recalled Product
Product
Package Size
NDC
Lot Number
Expiration Date
Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg
100-count bottle
51991-817-01
PK25110035
May 2029
What Consumers Should Do
Consumers should immediately stop taking product from the lot subject to this recall and contact their physician or healthcare provider for medical advice and replacement instructions. Consumers should return any unused portion of the affected product to the pharmacy where it was obtained.
Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this product.
Wholesalers, pharmacies, and other retail entities should check inventory for the recalled lot, quarantine any affected product, and not distribute or dispense the affected product. Entities that further distributed the product should notify their sub-accounts to the retail level.
For questions or concerns regarding this recall, contact Qualanex, Breckenridge’s designated recall service provider, Monday through Friday, 9:00 a.m. to 5:00 p.m. Eastern Time:
Phone : 1-855-736-0807 Email : recall@qualanex.com
Reporting Adverse Events
Adverse reactions or quality problems experienced with the use of this product may be reported to the U.S. Food and Drug Administration’s MedWatch Adverse Event Reporting program:
Online : www.fda.gov/medwatch/report.htm Mail or fax : Download the reporting form at www.fda.gov/MedWatch/getforms.htm , or call 1-800-332-1088 to request a form. Complete and return the form to the address provided, or fax it to 1-800-FDA-0178.
This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

